Clinical trials
Metastatic Breast Carcinoma clinical trials
Below are recruiting metastatic breast carcinoma clinical trials, each written for real people, not researchers. We’re tracking 404 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05544240RecruitingPhase 1
First-in-human immunotherapy study for advanced solid tumors
This Phase 1 trial tests SYNC-T, an immunotherapy, in people with advanced or metastatic solid cancers. It aims to find the safest dose and see whether the treatment can shrink or control tumors.
Mexico CityAges 18 years+ - NCT07608848RecruitingEarly Phase 1
Imaging study of new cancer-targeting radioactive drugs
This study tests two new radioactive drugs designed to find and image advanced breast or prostate cancer. The drugs use special imaging scans (PET and SPECT) to locate tumors and may help guide future treatment decisions.
Perth, Western AustraliaAges 18 years+ - NCT06800612Recruiting
Cancer drug therapy study for gynecologic or breast cancers
This study looks at how well different cancer drugs work for women with breast or gynecologic cancers. Researchers will review medical records to see how patients responded to treatment over time. If you have been treated for breast or gynecologic cancer since 2010, you may be eligible.
BolognaAges 18 years+ - NCT06241599RecruitingPhase 2/Phase 3
AK104 with chemo for advanced nasopharyngeal cancer
This study tests if adding a new immunotherapy drug (called AK104) to standard chemotherapy can help people whose nasopharyngeal cancer has come back or spread after previous treatment. The goal is to see if the combination works better than chemotherapy alone.
Guangzhou, GuangdongAges 18–75 - NCT05575804RecruitingPhase 1/Phase 2
GQ1001 plus pyrotinib for HER2-positive metastatic breast cancer
This trial tests a combination of two targeted drugs, GQ1001 and pyrotinib, for people with HER2-positive breast cancer that has spread to other parts of the body and has not responded to at least one prior treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07766018RecruitingPhase 2
Elacestrant for advanced or metastatic breast cancer
This trial tests a new hormone therapy pill, elacestrant, for people with a specific type of breast cancer (ER+, HER2-) that has a certain genetic change (ESR1 mutation) and has grown despite previous hormone therapy. The goal is to see if this drug can help control the cancer.
IseharaAges 18 years+ - NCT06784921Recruiting
Study of sacituzumab govitecan for HER2-negative breast cancer
This study looks at how well a drug called sacituzumab govitecan works and how safe it is for people with a certain type of breast cancer that has spread (HER2-negative metastatic breast cancer). It aims to understand real-world results for patients in China.
Hangzhou, ZhejiangAges 18–75 - NCT04660435Recruiting
Study how breast cancers resist CDK4/6 inhibitor treatment
This study looks at why some ER-positive, HER2-negative metastatic breast cancers don’t respond well to CDK4/6 inhibitors combined with hormone therapy. It may help researchers understand resistance and improve future treatment choices for people like you.
Prato, TuscanyAges Any age - NCT07087860RecruitingPhase 2
Plasma exchange plus targeted therapy for advanced bladder cancer
This trial tests a procedure called therapeutic plasma exchange (TPE) combined with the drugs enfortumab vedotin and pembrolizumab for people with advanced bladder cancer that has stopped responding to standard treatments. The goal is to see if TPE helps the drugs work better.
Rochester, MinnesotaAges 18 years+ - NCT07233928Recruiting
Breast cancer protein study in different subtypes
This trial takes a close look at the proteins inside breast cancer cells, using samples from people with different subtypes. It aims to better understand how each type behaves, which could help guide future treatments.
ToulouseAges 18 years+ - NCT06044623RecruitingPhase 3
Tailoring cancer pill dosing for older adults with breast cancer
This trial is testing whether adjusting the dose of a targeted therapy (CDK 4/6 inhibitor) based on a geriatric assessment can be as effective and safer for people aged 70 and older with advanced hormone receptor-positive, HER2-negative breast cancer. It aims to find the best dose to balance benefits and side effects.
HelsinkiAges 70 years+ - NCT06440005RecruitingPhase 1
Testing AGX101 for advanced solid tumors
This study tests a new drug called AGX101 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06524544RecruitingPhase 3
Pembrolizumab and sacituzumab govitecan for advanced bladder cancer
This trial tests a new drug combination (pembrolizumab and sacituzumab govitecan) against standard treatment for advanced bladder cancer that has spread or cannot be removed by surgery. It's for people who have already tried an immunotherapy drug like pembrolizumab and another drug called enfortumab vedotin.
Phoenix, ArizonaAges 18 years+ - NCT05720260RecruitingPhase 2
Test immunotherapy plus hormone therapy and an AKT blocker
This trial tests whether combining immunotherapy, hormone therapy, and an AKT-blocking drug can control ER-positive advanced breast cancer in women whose cancer is resistant to hormone treatment. It may help shrink tumors and slow disease by targeting several pathways at once.
TaipeiAges 20 years+ - NCT05301881RecruitingPhase 2
Keep the same treatment after limited metastatic growth
This study tests whether continuing your current systemic (whole-body) therapy is safe and helpful when only 1–2 metastatic spots start growing. It also checks whether adding local treatment (such as radiation or ablation) to those spots can better control the cancer.
AlkmaarAges 18 years+ - NCT05394259RecruitingPhase 1
PYLARIFY PET-CT scan to find spread in certain cancers
This early study tests whether a special PET-CT scan called PYLARIFY can detect metastasis (cancer spread) more effectively in pancreatic, liver (HCC), and breast cancers. If the scan results change doctors’ treatment plans, it could help you get the right next therapy sooner.
Houston, TexasAges 18 years+ - NCT05455619RecruitingPhase 1/Phase 2
Targeted drugs for PI3K-altered, HR+/HER2- breast cancer
This Phase 1/2 trial tests how well a combination of targeted medicines works for advanced or returning HR+/HER2- breast cancer that has a PI3K pathway change (such as PIK3CA, PTEN, or AKT1). It may help by blocking growth signals in the cancer and is especially for people whose cancer has progressed after hormone therapy and a CDK4/6 inhibitor.
Loma Linda, CaliforniaAges 18 years+ - NCT05716893RecruitingPhase 2
Aerobic exercise program for people getting breast cancer treatment
This Phase 2 study tests whether a supervised aerobic (cardio) training program can improve health and exercise capacity for people receiving treatment for primary breast cancer. You may join if you currently do very little moderate-to-vigorous exercise and can safely complete a special treadmill test that measures breathing and heart response.
Basking Ridge, New JerseyAges 18 years+ - NCT07593820RecruitingPhase 1
CAR-T Cell Study for Advanced HER2-Positive Cancers
This early-stage trial tests a new type of immune cell therapy called CAR-T cells, which are designed to recognize and attack cancer cells that have a protein called HER2. The cells are made from your own immune cells, trained in the laboratory, and given back to you. The study evaluates how safe the treatment is and whether it can shrink tumors.
Barcelona, CataloniaAges 18 years+ - NCT05696626RecruitingPhase 3
Test a new pill plus abemaciclib versus standard therapy
This Phase 3 study compares lasofoxifene plus abemaciclib versus fulvestrant plus abemaciclib for ER-positive, HER2-negative breast cancer that has an ESR1 mutation. It looks for better tumor control in people whose cancer has progressed on hormone therapy (an aromatase inhibitor) and who meet specific safety and testing requirements.
Scottsdale, ArizonaAges 18 years+ - NCT07705334RecruitingPhase 1
Study of SHY-ONC6 for advanced solid tumors
This trial tests a new drug called SHY-ONC6 that targets and breaks down cancer cells. It's for people with advanced solid tumors that haven't responded to standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT05205200RecruitingPhase 2
Immune therapy for HR-positive, HER2-negative metastatic breast cancer
This Phase 2 trial studies an immune-based treatment for women with HR-positive and HER2-negative breast cancer that has spread or returned and can’t be cured with local treatment alone. The goal is to see whether the therapy can shrink tumors and improve disease control with acceptable safety.
ShanghaiAges 18–75 - NCT07369505RecruitingPhase 1
A study of Sapu003 for advanced tumors sensitive to mTOR
This trial tests a new drug, Sapu003, in people with certain advanced cancers that may respond to mTOR-targeted therapy. It is looking at two groups: postmenopausal women with a type of breast cancer (HR+/HER2-), and adults with kidney, liver, neuroendocrine, or TSC-related tumors. The goal is to see if Sapu003 is safe and effective.
AdelaideAges 18 years+ - NCT06450314RecruitingPhase 2
De-escalating treatment for advanced HER2-positive breast cancer
This trial tests whether it's safe to reduce or stop some cancer treatments for people whose advanced HER2-positive breast cancer has been well-controlled for at least 2 years and has no detectable cancer cells in blood tests.
RennesAges 18 years+
Hear when a new Metastatic Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic breast carcinoma?
- Yes. Clin2 currently lists 404 recruiting metastatic breast carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic breast carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic breast carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Triple-Negative Breast Carcinoma
- Metastatic HER2-Negative Breast Carcinoma
- Metastatic Hormone Receptor-Positive Breast Carcinoma
- Metastatic Breast Cancer
- Breast Carcinoma
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Metastatic Renal Cell Carcinoma
- Metastatic Clear Cell Renal Cell Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.